Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antroquinonol - Golden Biotechnology Corporation

Drug Profile

Antroquinonol - Golden Biotechnology Corporation

Alternative Names: Hocena

Latest Information Update: 09 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Golden Biotechnology Corporation
  • Developer China Sky One Medical; Golden Biotechnology Corporation; Queensland University of Technology
  • Class Alkenes; Anti-inflammatories; Antidementias; Antihyperlipidaemics; Antineoplastics; Antivirals; Cyclohexenes; Ketones; Skin disorder therapies; Small molecules
  • Mechanism of Action Epidermal growth factor receptor modulators; Mitogen-activated protein kinase modulators; Proto oncogene protein c akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Acute myeloid leukaemia; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Atopic dermatitis; Colorectal cancer; Hepatitis B; Hyperlipidaemia; Non-small cell lung cancer; Pancreatic cancer
  • Preclinical Alzheimer's disease
  • No development reported Cancer

Most Recent Events

  • 01 Oct 2019 Golden Biotechnology Corporation and Chung Shan Medical University terminates a phase II trial in Atopic dermatitis due to non availability of suitable patients in Taiwan (PO) (NCT04110873)
  • 11 Sep 2019 Golden Biotechnology Corporation completes a phase II trial in Atopic dermatitis in Taiwan (PO) (NCT03622463)
  • 31 May 2019 Adverse events data from a phase II trial in Non-small cell lung cancer presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top